Explore the words cloud of the NOC project. It provides you a very rough idea of what is the project "NOC" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-12-01 to 2017-05-31|
Take a look of project's partnership.
Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).
MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions
NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NOC" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More